Oncologic imaging in gynecologic malignancies

Journal of Nuclear Medicine

Volumn 46, Issue 11, 2005, Pages 1842-1850

  Pandit Taskar, Neeta ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Gynecologic malignancy; Oncology; Ovarian cancer; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; ENDOMETRIUM CANCER; HUMAN; LYMPH NODE DISSECTION; LYMPHOSCINTIGRAPHY; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENTINEL LYMPH NODE; SURGICAL TECHNIQUE; TREATMENT PLANNING; UTERINE CERVIX CANCER; VAGINA CANCER; VULVA CANCER; CLINICAL PRACTICE; FEMALE; FEMALE GENITAL TRACT TUMOR; LYMPH NODE; LYMPH NODE METASTASIS; METHODOLOGY; ONCOLOGY; PRACTICE GUIDELINE; REVIEW; SCINTISCANNING;

FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MEDICAL ONCOLOGY; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES;

EID: 33644825499     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (106)

1. National cancer institute surveillance, epidemiology, and end results (NCI SEER) program. Available at: http://seer.cancer.gov;2003. Accessed July 8, 2004.
2. Wahl RL. Why nearly all PET of abdominal and pelvic cancers will be performed as PET/CT. J Nucl Med. 2004;45(suppl):82S-95S.
3. Subhas N, Patel PV, Pannu HK, Jacene HA, Fishman EK, Wahl RL. Imaging of pelvic malignancies with in-line FDG PET-CT: case examples and common pitfalls of FDG PET. Radiographics. 2005;25:1031-1043.
4. Fenchel S, Grab D, Nuessle K, et al. Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings. Radiology. 2002;223:780-788.
5. Grab D, Flock E, Stohr I, et al. Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography. Gynecol Oncol. 2000;77:454-459.
6. Tjalma WA, Carp L, De Beeck BO. False-positive positron emission tomographic scan and computed tomography for recurrent vaginal cancer: pitfalls of modern imaging techniques. Gynecol Oncol. 2004;92:726-728.
7. Chander S, Meltzer CC, McCook BM. Physiologic uterine uptake of FDG during menstruation demonstrated with serial combined positron emission tomography and computed tomography. Clin Nucl Med. 2002;27:22-24.
8. 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT. J Nucl Med. 2004;45:266-271.
9. EC Hughes. The effect of enzymes upon metabolism, storage, and release of carbohydrates in normal and abnormal endometria. Cancer. 1976;38:487-502.
10. Lobo RA, Stanczyk FZ. New knowledge in the physiology of hormonal contraceptives.
11. Pazdur R, Coia LR, Hoskins WJ, Wagman LD, eds. Cancer Management: A Multidisciplinary Approach. 4th ed. Melville, NY: PRR Inc.; 1999:361-430.
12. Staging Classifications and Clinical Practice Guidelines of Gynaecologic Cancers. International Federation of Gynecology and Obstetrics Web site. Available at: http://www.figo.org/content/PDF/staging-booklet.pdf. Accessed September 13, 2005.
13. Hricak H, Lacey CG, Sandles LG, Chang YC, Winkler ML, Stern JL. Invasive cervical carcinoma: comparison of MR imaging and surgical findings. Radiology. 1988;166:623-631.
14. Togashi K, Morikawa K, Kataoka ML, Konishi J. Cervical cancer. J Magn Reson Imaging. 1998;8:391-397.
15. Walsh JW, Goplerud DR. Prospective comparison between clinical and CT staging in primary cervical carcinoma. AJR. 1981;137:997-1003.
16. Kim SH, Choi BI, Han JK, et al. Preoperative staging of uterine cervical carcinoma: comparison of CT and MRI in 99 patients. J Comput Assist Tomogr. 1993;17:633-640.
17. 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression. J Nucl Med. 2004;45:22-29.
18. Wong TZ, Jones EL, Coleman RE. Positron emission tomography with 2-deoxy-2-[(18)F]fluoro-D-glucose for evaluating local and distant disease in patients with cervical cancer. Mol Imaging Biol. 2004;6:55-62.
19. Park W, Park YJ, Huh SJ, et al. The usefulness of MRI and PET imaging for the detection of parametrial involvement and lymph node metastasis in patients with cervical cancer. Jpn J Clin Oncol. 2005;35:260-264.
20. Tran BN, Grigsby PW, Dehdashti F, Herzog TJ, Siegel BA. Occult supraclavicular lymph node metastasis identified by FDG-PET in patients with carcinoma of the uterine cervix. Gynecol Oncol. 2003;90:572-576.
21. Weber TM, Sostman HD, Spritzer CE, et al. Cervical carcinoma: determination of recurrent tumor extent versus radiation changes with MR imaging. Radiology. 1995;194:135-139.
22. Havrilesky LJ, Wong TZ, Secord AA, Berchuck A, Clarke-Pearson DL, Jones EL. The role of PET scanning in the detection of recurrent cervical cancer. Gynecol Oncol. 2003;90:186-190.
23. Spottswood SE, Lopatina OA, Fey GL, Boardman CH. Peritoneal carcinomatosis from cervical cancer detected by F-18 FDG positron emission tomography. Clin Nucl Med. 2005;30:56-59.
24. Havrilesky LJ, Kulasingam SL, Matchar DB, Myers ER. FDG-PET for management of cervical and ovarian cancer. Gynecol Oncol. 2005;97:183-191.
25. Unger JB, Ivy JJ, Connor P, et al. Detection of recurrent cervical cancer by whole-body FDG PET scan in asymptomatic and symptomatic women. Gynecol Oncol. 2004;94:212-216.
26. Chang TC, Law KS, Hong JH, et al. Positron emission tomography for unexplained elevation of serum squamous cell carcinoma antigen levels during follow-up for patients with cervical malignancies: a phase II study. Cancer. 2004;101:164-171.
27. Chang WC, Hung YC, Lin CC, Shen YY, Kao CH. Usefulness of FDG-PET to detect recurrent cervical cancer based on asymptomatically elevated tumor marker serum levels: a preliminary report. Cancer Invest. 2004;22:180-184.
28. 18F-FDG PET for recurrent cervical cancer. J Nucl Med. 2004;45:1632-1639.
29. 18F]fluoro-2-deoxy-D-glucose positron emission tomography. Cancer. 2004;100:544-552.
30. Ma SY, See LC, Lai CH, et al. Delayed (18)F-FDG PET for detection of paraaortic lymph node metastases in cervical cancer patients. J Nucl Med. 2003;44:1775-1783.
31. Yen TC, Ng KK, Ma SY, et al. Value of dual-phase 2-fluoro-2-deoxy-d- glucose positron emission tomography in cervical cancer. J Clin Oncol. 2003;21:3651-3658. [published correction appears in J Clin Oncol. 2004;22:209].
32. Lin WC, Hung YC, Yeh LS, Kao CH, Yen RF, Shen YY. Usefulness of (18)F-fluorodeoxyglucose positron emission tomography to detect para-aortic lymph nodal metastasis in advanced cervical cancer with negative computed tomography findings. Gynecol Oncol. 2003;89:73-76.
33. Singh AK, Grigsby PW, Dehdashti F, Herzog TJ, Siegel BA. FDG-PET lymph node staging and survival of patients with FIGO stage IIIb cervical carcinoma. Int J Radiat Oncol Biol Phys. 2003;56:489-493.
34. Grigsby PW, Mutch DG, Rader J, et al. Lack of benefit of concurrent chemotherapy in patients with cervical cancer and negative lymph nodes by FDG-PET. Int J Radiat Oncol Biol Phys. 2005;61:444-449.
35. Grigsby PW, Singh AK, Siegel BA, Dehdashti F, Rader J, Zoberi I. Lymph node control in cervical cancer. Int J Radiat Oncol Biol Phys. 2004;59:706-712.
36. Yoshida Y, Kurokawa T, Kawahara K, et al. Metabolic monitoring of advanced uterine cervical cancer neoadjuvant chemotherapy by using [F-18]-fluorodeoxyglucose positron emission tomography: preliminary results in three patients. Gynecol Oncol. 2004;95:597-602.
37. 18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol. 2004;22:2167-2171.
38. Esthappan J, Mutic S, Malyapa RS, et al. Treatment planning guidelines regarding the use of CT/PET-guided IMRT for cervical carcinoma with positive paraaortic lymph nodes. Int J Radiat Oncol Biol Phys. 2004;58:1289-1297.
39. Mutic S, Malyapa RS, Grigsby PW, et al. PET-guided IMRT for cervical carcinoma with positive para-aortic lymph nodes: a dose-escalation treatment planning study. Int J Radiat Oncol Biol Phys. 2003;55:28-35.
40. Malyapa RS, Mutic S, Low DA, et al. Physiologic FDG-PET three-dimensional brachytherapy treatment planning for cervical cancer. Int J Radiat Oncol Biol Phys. 2002;54:1140-1146.
41. Fyles AW, Milosevic M, Wong R, et al. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol. 1998;48: 149-156.
42. Höckel M, Schlenger K, Aral B, Mitze M, Schäffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996;56:4509-4515.
43. Höckel M, Schlenger K, Mitze M, Schaffer U, Vaupel P. Hypoxia and radiation response in human tumors. Semin Radiat Oncol. 1996;6:3-9.
44. Höckel M, Schlenger K, Höckel S, Vaupel P. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res. 1999;59:4525-4528.
45. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med. 1997;38:1155-1160.
46. 60Cu-ATSM: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys. 2003;55:1233-1238.
47. Tanaka H, Yasuda Y, Musha T, Ueda K, Nakamura Y. Hypoxia correlates with angiogenesis in cervical cancers. Int J Clin Oncol. 2005;10:35-39.
48. Airley RE, Loncaster J, Raleigh JA, et al. GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding. Int J Cancer. 2003;104:85-91.
49. Airley R, Loncaster J, Davidson S, et al. Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res. 2001;7:928-934.
50. Bachtiary B, Schindl M, Potter R, et al. Overexpression of hypoxia-inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. Clin Cancer Res. 2003;9:2234-2240.
51. Pitson G, Fyles A, Milosevic M, Wylie J, Pintilie M, Hill R. Tumor size and oxygenation are independent predictors of nodal diseases in patients with cervix cancer. Int J Radiat Oncol Biol Phys. 2001;51:699-703.
52. 11C]choline. J Nucl Med. 1997;38:842-847.
53. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med. 1998;39:990-995.
54. Torizuka T, Kanno T, Futatsubashi M, et al. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET. J Nucl Med. 2003;44: 1051-1056.
55. 11C-methyl]-L- and D-methionine into a malignant glioma. Eur J Nucl Med. 1987;13:103-105.
56. 11C methionine uptake in tumor using positron emission tomography. J Nucl Med. 1989;30:1809-1813.
57. Lapela M, Leskinen-Kallio S, Varpula M, et al. Imaging of uterine carcinoma by carbon-11-methionine and PET. J Nucl Med. 1994;35:1618-1623.
58. Nahhas WA. Ovarian cancer: current outlook on this deadly disease. Postgrad Med. 1997;102:112-120.
59. Young RC, Fuks Z, Hoskins WJ. Cancer of the ovary. In: Devita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia, PA: J. B. Lippincott Co.
60. 18F]FDG). Gynecol Oncol. 1993;51:197-204.
61. Schroder W, Zimny M, Rudlowski C, Bull U, Rath W. The role of 18-F-flurorodeoxyglucose position imaging tomography 18-F-FGD PET in ovarian carcinoma. Int J Gynecol Cancer. 1999;9:117-122.
62. Yoshida Y, Kurokawa T, Kawahara K, et al. Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer. AJR. 2004;182:227-233.
63. Rose PG, Faulhaber P, Miraldi F, Abdul-Karim FW. Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy. Gynecol Oncol. 2001;82:17-21.
64. Drieskens O, Stroobants S, Gysen M, Vandenbosch G, Mortelmans L, Vergote I. Positron emission tomography with FDG in the detection of peritoneal and retroperitoneal metastases of ovarian cancer. Gynecol Obstet Invest. 2003;55: 130-134.
65. Turlakow A, Yeung HW, Salmon AS, Macapinlac HA, Larson SM. Peritoneal carcinomatosis: role of (18)F-FDG PET. J Nucl Med. 2003;44:1407-1412.
66. Smith GT, Hubner KF, McDonald T, Thie JA. Cost analysis of FDG PET for managing patients with ovarian cancer. Clin Positron Imaging. 1999;2:63-70.
67. 18F]FDG PET as a substitute for second-look laparotomy in patients with advanced ovarian carcinoma. Eur J Nucl Med Mol Imaging. 2004;31:196-201.
68. Delbeke D, Martin WH. Positron emission tomography imaging in oncology. Radiol Clin North Am. 2001;39:883-917.
69. 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer. Int J Clin Oncol. 2005;10:177-181.
70. Nanni C, Rubello D, Farsad M, et al. (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients. Eur J Surg Oncol. 2005;31:792-797.
71. Sironi S, Messa C, Mangili G, et al. Integrated FDG PET/CT in patients with persistent ovarian cancer: correlation with histologic findings. Radiology. 2004; 233:433-440.
72. 18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur Radiol. 2000;10:761-767.
73. Picchio M, Sironi S, Messa C, et al. Advanced ovarian carcinoma: usefulness of [(18)F]FDG-PET in combination with CT for lesion detection after primary treatment. Q J Nucl Med. 2003;47:77-84.
74. Barranger E, Kerrou K, Petegnief Y, David-Montefiore E, Cortez A, Darai E. Laparoscopic resection of occult metastasis using the combination of FDG-positron emission tomography/computed tomography image fusion with intra-operative probe guidance in a woman with recurrent ovarian cancer. Gynecol Oncol. 2005;96:241-244.
75. Lentz SS. Endometrial carcinoma diagnosed by positron emission tomography: a case report. Gynecol Oncol. 2002;86:223-224.
76. Nakahara T, Fujii H, Ide M, et al. F-18 FDG uptake in endometrial cancer. Clin Nucl Med. 2001;26:82-83.
77. Belhocine T, De Barsy C, Hustinx R, Willems-Foidart J. Usefulness of (18)F-FDG PET in the post-therapy surveillance of endometrial carcinoma. Eur J Nucl Med Mol Imaging. 2002;29:1132-1139.
78. Saga T, Higashi T, Ishimori T, et al. Clinical value of FDG-PET in the follow up of post-operative patients with endometrial cancer. Ann Nucl Med. 2003;17: 197-203.
79. Umesaki N, Tanaka T, Miyama M, et al. Positron emission tomography using 2-[(18)F] fluoro-2-deoxy-D-glucose in the diagnosis of uterine leiomyosarcoma: a case report. Clin Imaging. 2001;25:203-205.
80. Umesaki N, Tanaka T, Miyama M, et al. Positron emission tomography with (18)F-fluorodeoxyglucose of uterine sarcoma: a comparison with magnetic resonance imaging and power Doppler imaging. Gynecol Oncol. 2001;80:372-377.
81. Kelly JL III, Burke TW, Tornos C, et al. Minimally invasive vulvar carcinoma: an indication for conservative surgical therapy. Gynecol Oncol. 1991;144:240-244.
82. Cohn DE, Dehdashti F, Gibb RK, et al. Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer. Gynecol Oncol. 2002;85:179-184.
83. Cancer Facts & Figures. Atlanta, GA: American Cancer Society; 2005.
84. Lamoreaux WT, Grigsby PW, Dehdashti F, et al. FDG-PET evaluation of vaginal carcinoma. Int J Radiat Oncol Biol Phys. 2005;62:733-737.
85. Cabanas RM. An approach for the treatment of penile carcinoma. Cancer. 1977;39:456-466.
86. Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392-399.
87. Krag D, Weaver D, Ashikaga T, et al. The sentinel node in breast cancer: a multicenter validation study. N Engl J Med. 1998;339:941-946.
88. Harlow SP, Krag DN, Ashikaga T, et al. Gamma probe guided biopsy of the sentinel node in malignant melanoma: a multicentre study. Melanoma Res. 2001;11:45-55.
89. Decesare SL, Fiorica JV, Roberts WS, et al. A pilot study utilizing intraoperative lymphoscintigraphy for identification of the sentinel lymph nodes in vulvar cancer. Gynecol Oncol. 1997;66:425-428.
90. de Hullu JA, Doting E, Piers DA, et al. Sentinel lymph node identification with technetium-99m-labeled nanocolloid in squamous cell cancer of the vulva. J Nucl Med. 1998;39:1381-1385.
91. Sliutz G, Reinthaller A, Lantzsch T, et al. Lymphatic mapping of sentinel nodes in early vulvar cancer. Gynecol Oncol. 2002;84:449-452.
92. Merisio C, Berretta R, Gualdi M, et al. Radioguided sentinel lymph node detection in vulvar cancer. Int J Gynecol Cancer. 2005;15:493-497.
93. 99mTc-phytate for sentinel node mapping in melanoma, breast cancer and vulvar cancer: a study of 100 cases. Eur J Nucl Med. 2001;28:1597-604.
94. Louis-Sylvestre C, Evangelista E, Leonard F, Itti E, Meignan M, Paniel BJ. Sentinel node localization should be interpreted with caution in midline vulvar cancer. Gynecol Oncol. 2005;97:151-154.
95. Verheijen RHM, Pijpers R, van Diest PJ, et al. Sentinel node detection in cervical cancer. Obstet Gynecol. 2000;96:135-138.
96. Lantzsch T, Wolters M, Grimm J, et al. Sentinel node procedure in Ib cervical cancer: a preliminary series. Br J Cancer. 2001;85:791-794.
97. Malur S, Krause N, Kohler C, et al. Sentinel lymph node detection in patients with cervical cancer. Gynecol Oncol. 2001;80:254-257.
98. Levenback C, Coleman RL, Burke TW, et al. Lymphatic mapping and sentinel node identification in patients with cervix cancer undergoing radical hysterectomy and pelvic lymphadenectomy. J Clin Oncol. 2002;20:688-693.
99. Pijpers R, Buist MR, van Lingen A, et al. The sentinel node in cervical cancer: scintigraphy and laparoscopic gamma probe-guided biopsy. Eur J Nucl Med Mol Imaging. 2004;31:1479-1486.
100. Martinez-Palones JM, Gil-Moreno A, Perez-Benavente MA, Roca I, Xercavins J. Intraoperative sentinel node identification in early stage cervical cancer using a combination of radiolabeled albumin injection and isosulfan blue dye injection. Gynecol Oncol. 2004;92:845-850.
101. Van Dam P, Sonnemans H, van Dam PJ, Verkinderen L, Dirix LY. Sentinel node detection in patients with vaginal carcinoma. Gynecol Oncol. 2004;92: 89-92.
102. Burke TW, Levenback C, Tornos C, et al. Intraabdominal lymphatic mapping to direct selective pelvic and paraaortic lymphadenectomy in women with high-risk endometrial cancer: results of a pilot study. Gynecol Oncol. 1996;62:169-173.
103. 99mTc colloid and blue dye in patients with endometrial cancer. Tumori. 2002;88:S9-S10.
104. Pelosi E, Arena V, Baudino B, et al. Pre-operative lymphatic mapping and intra-operative sentinel lymph node detection in early stage endometrial cancer. Nucl Med Commun. 2003;24:971-975.
105. 99mTc-labelled albumin nanocolloid in endometrial cancer. Eur J Nucl Med Mol Imaging. 2005;32:569-574.
106. Niikura H, Okamura C, Utsunomiya H, et al. Sentinel lymph node detection in patients with endometrial cancer. Gynecol Oncol. 2004;92:669-674.